We’re excited to share that our study investigating nanoscale decoys as SARS-CoV-2 inhibitors is out in Small! We learned that engineered decoy nanoparticles are potent viral inhibitors and appear quite resistant to viral evolutionary escape. We hope that the design rules and performance metrics we identified will accelerate the development and preclinical evaluation of this exciting new class of antiviral therapeutics. Congratulations to Taylor, Devin, and Roxi and our excellent collaborator Dr. Neha Kamat. Check out the paper here! Additionally, check out some press about the paper here!
